# Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

> **NCT03516812** · PHASE2 · COMPLETED · sponsor: **University of Washington** · enrollment: 36 (actual)

## Conditions studied

- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Olaparib
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Survey Administration
- **DRUG:** Testosterone Enanthate
- **DRUG:** Testosterone Cypionate

## Key facts

- **NCT ID:** NCT03516812
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-29
- **Primary completion:** 2021-03-05
- **Final completion:** 2024-04-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03516812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03516812, "Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03516812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*